Thank you to @DrugInfoAssn for hosting the Evolution of Biosimilars Development Workshop. We're proud to continue advancing the industry, ensuring patients always have access to lower-cost treatments. Learn more about #biosimilars here: bit.ly/41Abbo7

As Congress looks for ways to lower the cost of healthcare, we must continue to develop the answer, more biosimilars. Visit the Biosimilars Forum’s website to learn more about the opportunities patients have to access lower-cost treatments. biosimilarsforum.org/news/

#Biosimilars have improved the healthcare industry, providing patients with access to effective, lower-cost medicines. We thank you and all those who attended the DIA Evolution of Biosimilars Development Workshop for supporting our industry. biosimilarsforum.org/

Tomorrow, join Biosimilars Forum Executive Director Julie Reed as she highlights the growth of the #biosimilars industry during the @DrugInfoAssn Evolution of Biosimilars Development Workshop. Learn more about the workshop here: bit.ly/4gWva5N

Developing more biosimilars means patients have increased access to lower-cost treatments. Learn more about the state of the #biosimilars industry at the DIA Evolution of Biosimilars Development Workshop: bit.ly/4gWva5N

Join the Biosimilars Forum and its members at the DIA Evolution of Biosimilars Development Workshop. Learn more about the conference here: diaglobal.org/en/conference-…

The DIA Evolution of Biosimilars Development Workshop is almost here! Next week, the Biosimilars Forum’s Executive Director, Julie Reed will address the state of the #biosimilars industry and the importance of streamlined development. Learn more: diaglobal.org/en/conference-…

Chronic diseases account for 90% of U.S. healthcare spending. Increased adoption of #biosimilars can provide quality care at a fraction of the cost. We will continue to urge Congress and the administration to dismantle the PBM monopoly that pushes high-rebate drugs for profit.

The Biosimilars Forum looks forward to the @DrugInfoAssn Evolution of Biosimilars Development Workshop this May. The Forum's Executive Director, Julie Reed, will deliver a state of the industry speech, with support from Forum members. Learn more: bit.ly/4gWva5N

Thank you, @festofbiologics, for hosting the Biosimilars Forum! Now is the time to streamline biosimilar development and ensure patients have access to lower-cost treatments. Learn more about #biosimilars: biosimilarsforum.org/biosimi… #festivalofbiologics

The Biosimilars Forum supports Chair of the Scientific Affairs Committee, Hillel Cohen, as he discusses the development of biosimilars today at the @festofbiologics.

#Biosimilars offer significant savings: $5.2B for U.S. taxpayers and $3.3B in out-of-pocket savings for #Medicare seniors. The Biosimilars Forum is working to make these savings a reality by increasing access and affordability.

The development of more FDA-approved biosimilars could save patients $181 billion over the next five years! Learn more about these life-saving medicines here: biosimilarsforum.org/ #festivalofbiologics

#Biosimilars are transforming healthcare by offering treatments that are, on average, 50% lower cost than the biologics they reference. Over the past decade, they’ve saved $56 billion and provided nearly 700 million days of therapy.

Executive Director of the Biosimilars Forum, Julie Reed, is proud to present a state of the industry at @DrugInfoAssn's Evolution of Biosimilars Development Workshop. Register now to gain access to dozens of in-person workshops and presentations: bit.ly/4gWva5N

FDA-approved #biosimilars meet the highest safety and quality standards, ensuring they are safe and effective. Patients and providers can trust that biosimilars undergo rigorous evaluation before approval. Learn more: fda.gov/drugs/biosimilars/re…

Next week, the Biosimilars Forum’s Chair of the Scientific Affairs Committee, Hillel Cohen, will discuss the development of future biosimilars. Learn more about @festofbiologics #festivalofbiologics: bit.ly/4bDMifA

Only one month until @DrugInfoAssn's Evolution of Biosimilars Development Workshop. Register now to join hundreds of industry leaders in the discussion on developing future biosimilars: bit.ly/4gWva5N

Over the last decade, #biosimilars have saved $56 billion compared to what spending would have been without them. Yet, high out-of-pocket costs still force some patients to delay or skip treatment. Policymakers must act to ensure biosimilars remain accessible and affordable.

Follow the Biosimilars Forum on LinkedIn to stay up to date on the latest #biosimilars news and events – including @DrugInfoAssn's Evolution of Biosimilars Development Workshop. Follow us here: linkedin.com/company/biosimi…